Literature DB >> 33555604

COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society.

Monika Nojszewska1, Alicja Kalinowska2, Monika Adamczyk-Sowa3, Alina Kułakowska4, Halina Bartosik-Psujek5.   

Abstract

A working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society has developed a statement with regard to the currently available mRNA vaccines (Pfizer-BioNTech and Moderna) preventing novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) infection, which causes Coronavirus disease 2019 (COVID-19), in patients with multiple sclerosis (MS). This statement has been based on the literature available as of 15 January, 2021. The guidance will be updated as new data emerges. All data regarding the above-mentioned vaccines comes from clinical trials which have been reviewed, published and approved by the regulatory authorities [1, 2]. In the current manuscript, whenever a SARS-CoV-2 vaccine is discussed, it refers to mRNA vaccines only.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; guidelines; multiple sclerosis; vaccines

Mesh：

Substances：

Year:  2021        PMID： 33555604     DOI： 10.5603/PJNNS.a2021.0016

Source DB:  PubMed          Journal:  Neurol Neurochir Pol        ISSN： 0028-3843            Impact factor:   1.621


  8 in total

Review 1.  Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?

Authors:  Shani Witman Tsur; Eli Adrian Zaher; Meydan Tsur; Karolina Kania; Alicja Kalinowska-Łyszczarz
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

Review 2.  An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations.

Authors:  Bulent Kantarcioglu; Omer Iqbal; Joseph Lewis; Charles A Carter; Meharvan Singh; Fabio Lievano; Mark Ligocki; Walter Jeske; Cafer Adiguzel; Grigoris T Gerotziafas; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

3.  Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland.

Authors:  Agata Czarnowska; Joanna Tarasiuk; Olga Zajkowska; Marcin Wnuk; Monika Marona; Klaudia Nowak; Agnieszka Słowik; Anna Jamroz-Wiśniewska; Konrad Rejdak; Beata Lech; Małgorzata Popiel; Iwona Rościszewska-Żukowska; Adam Perenc; Halina Bartosik-Psujek; Mariola Świderek-Matysiak; Małgorzata Siger; Agnieszka Ciach; Agata Walczak; Anna Jurewicz; Mariusz Stasiołek; Karolina Kania; Klara Dyczkowska; Alicja Kalinowska-Łyszczarz; Weronika Galus; Anna Walawska-Hrycek; Ewa Krzystanek; Justyna Chojdak-Łukasiewicz; Jakub Ubysz; Anna Pokryszko-Dragan; Katarzyna Kapica-Topczewska; Monika Chorąży; Marcin Bazylewicz; Anna Mirończuk; Joanna Kulikowska; Jan Kochanowicz; Marta Białek; Małgorzata Stolarz; Katarzyna Kubicka-Bączyk; Natalia Niedziela; Paweł Warmus; Monika Adamczyk-Sowa; Aleksandra Podlecka-Piçtowska; Monika Nojszewska; Beata Zakrzewska-Pniewska; Elżbieta Jasińska; Jacek Zaborski; Marta Milewska-Jȩdrzejczak; Jacek Zwiernik; Beata Zwiernik; Andrzej Potemkowski; Waldemar Brola; Alina Kułakowska
Journal:  Front Neurol       Date:  2022-06-14       Impact factor: 4.086

4.  COVID-19 infection and vaccination against COVID-19: Impact on managing demyelinating CNS disorders in Southern India- experience from a demyelinating disease registry.

Authors:  L Pandit; A Sudhir; C Malli; A D'Cunha
Journal:  Mult Scler Relat Disord       Date:  2022-07-05       Impact factor: 4.808

5.  Safety of Vaccines against SARS-CoV-2 among Polish Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies.

Authors:  Agata Czarnowska; Joanna Tarasiuk; Olga Zajkowska; Marcin Wnuk; Monika Marona; Klaudia Nowak; Agnieszka Słowik; Anna Jamroz-Wiśniewska; Konrad Rejdak; Beata Lech; Małgorzata Popiel; Iwona Rościszewska-Żukowska; Adam Perenc; Halina Bartosik-Psujek; Mariola Świderek-Matysiak; Małgorzata Siger; Agnieszka Ciach; Agata Walczak; Anna Jurewicz; Mariusz Stasiołek; Karolina Kania; Klara Dyczkowska; Alicja Kalinowska-Łyszczarz; Weronika Galus; Anna Walawska-Hrycek; Ewa Krzystanek; Justyna Chojdak-Łukasiewicz; Jakub Ubysz; Anna Pokryszko-Dragan; Katarzyna Kapica-Topczewska; Monika Chorąży; Marcin Bazylewicz; Anna Mirończuk; Joanna Kulikowska; Jan Kochanowicz; Marta Białek; Małgorzata Stolarz; Katarzyna Kubicka-Bączyk; Natalia Niedziela; Natalia Morawiec; Monika Adamczyk-Sowa; Aleksandra Podlecka-Piętowska; Monika Nojszewska; Beata Zakrzewska-Pniewska; Elżbieta Jasińska; Jacek Zaborski; Marta Milewska-Jędrzejczak; Jacek Zwiernik; Beata Zwiernik; Andrzej Potemkowski; Waldemar Brola; Alina Kułakowska
Journal:  Vaccines (Basel)       Date:  2022-05-12

6.  Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations.

Authors:  Hubert Mado; Monika Adamczyk-Sowa
Journal:  J Neurol       Date:  2021-04-16       Impact factor: 4.849

Review 7.  Nano-Microparticle Platforms in Developing Next-Generation Vaccines.

Authors:  Giuseppe Cappellano; Hugo Abreu; Chiara Casale; Umberto Dianzani; Annalisa Chiocchetti
Journal:  Vaccines (Basel)       Date:  2021-06-05

8.  Awareness of COVID-19 Symptoms, Risk Factors, and Vaccinations in Patients with Multiple Sclerosis.

Authors:  Ewa Krzystanek; Agata Jurczak; Kinga Kocur; Jakub Jurkiewicz; Aleksandra Kaczmarczyk
Journal:  Int J Environ Res Public Health       Date:  2022-03-12       Impact factor: 3.390
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.